Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rupatadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 18/20 | 1.00 |
| ▸ | PTAFR known ✓ | P25105 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | FNTA | P49354 | 2/20 | 0.60 |
| ▸ | FNTB | P49356 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rupatadine SCHEMBL30730975 | 1.00 | HRH1 (1.00) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL27703 | 1.00 | HRH1 (1.00) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL28585002 | 0.99 | HRH1 (0.98) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL1649670 | 0.99 | HRH1 (0.98) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL28086201 | 0.95 | HRH1 (0.90) | HRH1PTAFRKCNH2FNTAFNTB | |
| SCHEMBL16385871 | 0.93 | HRH1 (0.87) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL29602857 | 0.93 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL29101069 | 0.93 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL31116805 | 0.93 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL19474963 | 0.93 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633613-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH S.A. (ES) | 2025-10-22 | — | — | EP | claimed |
| CN-119053609-A | Crystal form of lubidine and preparation method thereof | 上海皓元医药股份有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-118388507-A | Crystal form of lubidine and preparation method thereof | 上海皓元医药股份有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-118236330-A | Rubitidine freeze-dried composition, rubitidine injection and preparation method thereof | 博瑞生物医药（苏州）股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| WO-2024126772-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH, S.A. (ES) | 2024-06-20 | — | — | WO | claimed |
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2026-05-07 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250388691-A1 | METHODS FOR TREATING LYMPHOMA | XENCOR INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4633613-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH S.A. (ES) | 2025-10-22 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022187556-A1 | THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING MAGNETIZABLE NANOPARTICLES | VRG STEM CELL SERVICES INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20220087938-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2022-03-24 | — | — | US | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | CYP2C19, PAICS, CYP2B6 | HRH1 1159/4885PTAFR 2963/4885KCNH2 2528/4885 |
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | SLC5A1, SLC5A2, GLP1R | HRH1 3021/4885PTAFR 636/4885KCNH2 3134/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | HRH1 530/4885PTAFR 3712/4885KCNH2 511/4885 |
| US-20250388691-A1 | METHODS FOR TREATING LYMPHOMA | IGLV6-57, BCL6, MALT1 | HRH1 990/4885PTAFR 4632/4885KCNH2 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.